H.C. Wainwright has revised its price target for Cogent Biosciences (COGT, Financial), lowering it to $12 from a previous $14, although the firm maintains a Buy rating on the stock. This adjustment follows the company's first-quarter financial results. The firm also anticipates an equity raise by Cogent Biosciences in the fourth quarter of this year.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Cogent Biosciences Inc (COGT, Financial) is $16.27 with a high estimate of $24.00 and a low estimate of $7.00. The average target implies an upside of 226.76% from the current price of $4.98. More detailed estimate data can be found on the Cogent Biosciences Inc (COGT) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Cogent Biosciences Inc's (COGT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
